Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial

The phase II AVASTEM trial explored the impact of chemotherapy-bevacizumab combination on breast cancer stem cells in the neoadjuvant setting. We aimed to identify biological features associated with preoperative chemotherapy efficacy and prognosis by analyses of circulating tumor cells (CTCs) and b...

Full description

Bibliographic Details
Main Authors: Renaud Sabatier, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, François-Clément Bidard, Jean-Marc Extra, Patrick Sfumato, Anthony Gonçalves
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
early breast cancer
bevacizumab
neoadjuvant chemotherapy
circulating tumor cells and pharmacokinetics
Online Access:https://www.mdpi.com/2072-6694/13/1/140

Internet

https://www.mdpi.com/2072-6694/13/1/140

Similar Items